eagleus.com (EGRX) - Bathi sawise mbayar pajeg

Patents for injectable oncology and critical care products protect Eagle Pharmaceuticals (EGRX) from generic competitors, while the company's profit visualizes actual business revenues, where the 0.00 level records the latest values. The portfolio relies on intensive care drugs, expanding hospital reach. A stable staff of chemical technologists and compliance experts guarantees the development of new medical indications.

EGRX (Eagle Pharma) riwayat Bathi resik saka 04.07.2022 nganti 12.10.2024

Rincian analitis lan laporan data perusahaan eagleus.com (EGRX)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan bursa Eagle Pharmaceuticals, Inc.|EGRX - Target konsensus

- indikator kapitalisasi pasar:

Nilai pasar Eagle Pharmaceuticals, Inc.|EGRX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi Saham Eagle Pharmaceuticals|EGRX - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih eagleus.com|EGRX - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Total Utang marang Modal Eagle Pharmaceuticals|EGRX - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Eagle Pharmaceuticals, Inc.|EGRX - Gunggung utang perusahaan|Utang marang nilai buku Eagle Pharmaceuticals, Inc.|EGRX - Utang jangka dawa perusahaan|Utang jangka cendhak Eagle Pharmaceuticals|Rasio jangkoan perantara eagleus.com

- indikator pendapatan resik lan kelipatan nilai:

EGRX - Bathi resik

Pambiji fundamental:EGRX, Eagle Pharma

Eagle Pharmaceuticals (EGRX) profit represents the final financial result after deducting all operating and tax expenses, reflecting the actual efficiency of the business's value generation. The company's net income trend allows for an assessment of how the launch of new generics and the oncology pipeline impact capitalization, confirming the viability of the strategy to introduce niche drugs into the hospital market.

Pesaing langsung